CRIS Current Research Information System

TAVOLARI, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.194
NA - Nord America 4.183
EU - Europa 2.582
AF - Africa 271
SA - Sud America 177
OC - Oceania 5
AN - Antartide 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.414
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.124
CN - Cina 1.118
SG - Singapore 1.115
VN - Vietnam 1.087
IT - Italia 491
GB - Regno Unito 451
SE - Svezia 329
DE - Germania 295
HK - Hong Kong 221
FR - Francia 174
IN - India 161
KR - Corea 144
CH - Svizzera 136
IE - Irlanda 132
BR - Brasile 112
FI - Finlandia 100
RU - Federazione Russa 99
NL - Olanda 96
UA - Ucraina 82
BD - Bangladesh 71
CI - Costa d'Avorio 63
ZA - Sudafrica 56
TG - Togo 55
JP - Giappone 52
SC - Seychelles 51
CA - Canada 39
JO - Giordania 38
BE - Belgio 34
ID - Indonesia 30
PH - Filippine 30
NG - Nigeria 28
EE - Estonia 26
BG - Bulgaria 24
AT - Austria 20
AR - Argentina 19
PL - Polonia 18
TH - Thailandia 18
TR - Turchia 16
CL - Cile 13
IQ - Iraq 13
GR - Grecia 12
TW - Taiwan 12
EC - Ecuador 11
HR - Croazia 11
PK - Pakistan 11
SA - Arabia Saudita 11
ES - Italia 10
LT - Lituania 8
MX - Messico 8
MY - Malesia 8
RO - Romania 8
UZ - Uzbekistan 8
IR - Iran 7
PS - Palestinian Territory 7
CO - Colombia 6
AU - Australia 5
PE - Perù 5
PT - Portogallo 5
JM - Giamaica 4
PY - Paraguay 4
TN - Tunisia 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
CR - Costa Rica 3
DK - Danimarca 3
DZ - Algeria 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
CZ - Repubblica Ceca 2
EG - Egitto 2
HN - Honduras 2
HU - Ungheria 2
IL - Israele 2
LB - Libano 2
MA - Marocco 2
MT - Malta 2
NP - Nepal 2
RS - Serbia 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AO - Angola 1
AQ - Antartide 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
GE - Georgia 1
GF - Guiana Francese 1
GH - Ghana 1
GI - Gibilterra 1
KE - Kenya 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
MC - Monaco 1
NE - Niger 1
Totale 11.411
Salva come PNG Salva come JPEG
Città #
Singapore 801
Ashburn 425
Chandler 379
Southend 369
Hefei 329
Dallas 300
Ho Chi Minh City 258
Fairfield 246
San Jose 242
Dong Ket 213
Hanoi 208
Hong Kong 207
Santa Clara 164
Houston 152
Bologna 139
Dublin 132
Seoul 128
Bern 125
Boardman 123
Beijing 122
Princeton 115
Wilmington 115
Ann Arbor 108
Woodbridge 108
New York 99
Seattle 99
Cambridge 90
Helsinki 81
Council Bluffs 74
Abidjan 63
Lauterbourg 62
Los Angeles 59
Lomé 55
Frankfurt am Main 47
Jacksonville 47
Tokyo 45
Nanjing 43
Da Nang 40
Milan 39
Westminster 38
Amman 36
Berlin 34
Buffalo 34
Bengaluru 33
Rome 32
Brussels 31
Haiphong 31
Padova 30
Guangzhou 28
Redondo Beach 28
Jinan 27
Redmond 26
San Diego 25
Sofia 24
Jakarta 23
Shanghai 22
São Paulo 21
London 20
Medford 18
Abeokuta 17
Chicago 17
Johannesburg 17
Shenyang 17
Toronto 16
Munich 15
Changsha 14
Lappeenranta 14
Mülheim 14
Phoenix 14
Turin 14
Zhengzhou 14
Can Tho 13
Orem 13
Quận Ba 13
San Francisco 13
The Dalles 13
Tongling 13
Biên Hòa 12
Florence 12
Hebei 12
Montreal 12
Nanchang 12
Vienna 12
Amsterdam 11
Fremont 11
Jiaxing 11
Rimini 11
Warsaw 11
Des Moines 10
Kuban 10
Nuremberg 10
Saint Petersburg 10
Hải Dương 9
Olalla 9
Shenzhen 9
Atlanta 8
Bühl 8
Dearborn 8
Denver 8
Norwalk 8
Totale 7.507
Salva come PNG Salva come JPEG
Nome #
Adjuvant treatment in biliary tract cancer 345
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 303
Simple and dendritic cyclam derivative. Photophysical properties, effect of protonation and Zn++ coordination, preliminary screening as inhibitors of tumor cell growth 256
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations 250
Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment 249
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 249
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 243
Antitumoral Efficacy of Two Turmeric Extracts According to Different Extraction Methods in Hepatocellular Carcinoma Cell Lines 243
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 229
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 228
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 219
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 219
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland 216
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 208
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 208
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 207
219 MiR-21 expression correlates with prognosis in extrahepatic radically resected cholangiocarcinomas treated with gemcitabine-based adjuvant chemotherapy 205
Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. 204
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 202
Angiogenesis modulation in human umbilical endothelial vein (HUVE) cells by selected polychlorobiphenyls congeners is mediated by estrogen receptor alpha (ERα) binding. 200
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 200
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 197
Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma 196
In Reply 195
Selected polychlorobiphenyls congeners bind to estrogen receptor alpha in human umbilical vascular endothelial (HUVE) cells modulating angiogenesis 182
The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA-7 colon cancer cells. 182
Annellated pyrrole compounds for cancer management 181
Cholangiocarcinoma: Epidemiology and risk factors 181
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 180
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies 179
Annellated pyrrole compounds for cancer management 178
Immunomodulation by 17beta-estradiol in bivalve hemocytes. 174
The basal-like breast carcinoma phenotype is regulated by SLUG gene expression 171
Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner 170
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) to predict better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 170
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 169
Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review 168
Decreasing Albumin mRNA Expression in Cholangiocarcinomas along the Bile Duct Tree. 166
Intestinal Microbiota Increases Cell Proliferation of Colonic Mucosa in Human-Flora-Associated (HFA) Mice 166
The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action 166
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 162
MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. 158
Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link 157
Classic versus innovative strategies for immuno-therapy in pancreatic cancer 153
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 149
Effect of the serine proteases inhibitor gabexate mesylate (GM) on the activity of gemcitabine (G) in cell lines of pancreatic cancer (PC) 146
Genomic And Genetic Characterization of Cholangiocarcinoma Identifies Therapeutics Targets for Tyrosine Kinase Inhibitors 145
Re: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. 144
IN VIVO/IN VITRO AGED FIBROBLASTS TRIGGER MALIGNANT FEATURES IN NORMAL AND CANCER STEM/PROGENITOR CELLS OF THE MAMMARY GLAND 142
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue 139
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 128
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) predicts better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 127
Improvements in Systemic Therapies for Advanced Malignant Mesothelioma 121
Evolution of the experimental models of cholangiocarcinoma 119
Asbestos and Intrahepatic Cholangiocarcinoma 114
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. 112
Carcinogenesis of Cholangiocarcinoma 112
The protease inhibitor gabexate Mesylate has antitumor effects and enhances gemcitabine action on pancreatic cancer cell lines 112
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 111
TUSC3 accelerates cancer growth and induces epithelial-mesenchymal transition by upregulating claudin-1 in non-small-cell lung cancer cells 104
Nivolumab: an investigational agent for the treatment of biliary tract cancer 102
null 99
Have We Found the “Holy Grail” That May Predict Response to Immunotherapy in Hepatocellular Carcinoma? 91
Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma 90
Circulating tumor DNA in biliary tract cancer: Current evidence and future perspectives 89
Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma 88
TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. 85
Current and novel therapeutic opportunities for systemic therapy in biliary cancer 73
Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma 31
Totale 11.657
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.849
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.849
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021245 0 0 0 0 0 0 0 0 0 0 0 245
2021/20221.143 100 35 63 83 75 39 26 57 109 95 234 227
2022/20231.586 166 232 91 186 99 108 31 99 250 41 103 180
2023/2024422 54 59 22 34 34 97 14 25 10 31 15 27
2024/20251.666 70 209 163 122 199 82 112 51 30 139 133 356
2025/20264.754 430 558 586 341 427 226 520 158 765 339 208 196
Totale 11.657